Several brokerages have updated their recommendations and price targets on shares of Dynavax Technologies Corp. (NASDAQ: DVAX) in the last few weeks:

  • 9/14/2016 – Dynavax Technologies Corp. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 9/7/2016 – Dynavax Technologies Corp. had its “sector perform” rating reaffirmed by analysts at RBC Capital Markets. They now have a $16.00 price target on the stock.
  • 9/6/2016 – Dynavax Technologies Corp. had its “buy” rating reaffirmed by analysts at William Blair. They now have a $45.00 price target on the stock.
  • 9/6/2016 – Dynavax Technologies Corp. had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $45.00 price target on the stock.
  • 9/5/2016 – Dynavax Technologies Corp. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 9/2/2016 – Dynavax Technologies Corp. had its price target raised by analysts at S&P Equity Research from $11.28 to $16.01.
  • 8/30/2016 – Dynavax Technologies Corp. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 8/24/2016 – Dynavax Technologies Corp. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 8/16/2016 – Dynavax Technologies Corp. was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 8/10/2016 – Dynavax Technologies Corp. was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “

Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) traded down 0.43% on Thursday, reaching $11.62. The company’s stock had a trading volume of 964,337 shares. Dynavax Technologies Corp. has a 12 month low of $10.14 and a 12 month high of $29.86. The firm’s 50-day moving average price is $14.58 and its 200-day moving average price is $16.20. The stock’s market cap is $447.34 million.

Dynavax Technologies Corp. (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.07. The firm had revenue of $2.65 million for the quarter, compared to the consensus estimate of $1.58 million. Dynavax Technologies Corp. had a negative return on equity of 64.43% and a negative net margin of 2,068.75%. The firm’s revenue was up 70.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.80) EPS. On average, analysts forecast that Dynavax Technologies Corp. will post ($2.96) earnings per share for the current fiscal year.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

Receive News & Ratings for Dynavax Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.